EpiVax Doubles Providence Lab Capacity to Scale Immunogenicity Testing
Facing a shifting regulatory landscape that increasingly prioritizes human-relevant data over traditional animal models, Providence-based EpiVax has more than doubled its laboratory footprint. This expansion is designed to meet the surging demand for new approach methodologies, or NAMs, which help developers identify immune risks long before clinical trials begin.
The upgraded facility enables the company to integrate its proprietary in silico tools with a broader suite of in vitro assays. By utilizing human whole blood, PBMCs, and specialized antigen-presenting cells like dendritic cells, EpiVax aims to provide a modular platform that scales with the specific needs of biologics, peptides, and biosimilars. These cellular readouts—ranging from cytokine secretion to complex phenotyping—work in tandem with the firm’s ISPRI toolkit to create a unified risk assessment framework.
This infrastructure supports a mechanistic approach to drug development, moving away from late-stage clinical observations toward early-stage characterization. The company’s PANDA screening framework, which has already underpinned more than 16 successful global regulatory submissions, serves as a blueprint for this strategy. According to Vibha Jawa, Ph.D., CSO of EpiVax, the investment is intended to give therapeutic developers the data-driven insights necessary to navigate the entire development lifecycle, from initial discovery through to eventual commercialization.
Comments (0)
No comments yet. Be the first!